-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56

Benzinga·09/08/2026 14:17:25
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.